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Abstract 24 
Biopsies, in the form of tissue microarrays (TMAs) were studied to identify anomalies indicative 25 
of prostate cancer at the proteome level. TMAs offer a valuable source of well-characterized 26 
biological material. However, because of the small tissue sample size method development was 27 
essential to provide the sensitivity and reliability necessary for the analysis. Surface digestion of 28 
TMA cores was followed by peptide extraction and shotgun proteomics analysis. About 5 times 29 
better sensitivity was achieved by the optimized surface digestion compared to bulk digestion of 30 
the same TMA spot and it allowed the identification of over 500 proteins from individual prostate 31 
TMA cores. Label-free quantitation showed that biological variability among all samples was 32 
about 3 times larger than the technical reproducibility. We have identified 189 proteins which 33 
showed statistically significant changes (t-test p-value < 0.05) in abundance between healthy and 34 
cancerous tissue samples. The proteomic profile changed according to cancer grade, but did not 35 
show a correlation with cancer stage. Results of this pilot study were further evaluated using 36 
bioinformatics tools, identifying various protein pathways affected by prostate cancer progression 37 
indicating the usefulness of studying TMA cores to identify quantitative changes in tissue 38 
proteomics. 39 
Significance 40 
Detailed proteomics analysis of TMAs presents a good alternative for tissue analysis. Here we 41 
present a novel method, based on tissue surface digestion and nano-LC-MS measurements, which 42 
is capable of identifying and quantifying over 500 proteins from a 1.5 mm diameter tissue section. 43 
We compared healthy and cancerous prostate tissues samples, and tissues with various grades and 44 
stages of cancer. Tissue proteomics clearly distinguished healthy and cancerous samples, 45 
furthermore the results correlated well with cancer grade, but not with cancer stage. Over 100 46 
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proteins showed statistically significant abundance changes (t-test p-value < 0.05) between various 47 
groups. This was sufficient for a meaningful bioinformatics evaluation; showing e.g. increased 48 
abundance of proteins in cancer in the KEGG ribosome pathway, GO mRNA splicing via 49 
spliceosome, and chromatin assembly biological processes. The results highlight the feasibility of 50 
the developed method for future large-scale tissue proteomics studies using commercially 51 
available TMAs. 52 
 53 
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1. Introduction 59 
Prostate cancer is among the top three most common types of cancer in men [1]. Tissue biopsies 60 
[2, 3] are frequent objects of mass spectrometry (MS) based research and could provide useful 61 
insights into understanding biochemical mechanisms of diseases, such as cancer. Detecting 62 
anomalies at the molecular level is essential for identifying potential drug targets and for 63 
developing new treatment options. Tissue microarrays (TMAs) are a pathologically well-64 
characterized source of biopsies fixed on a microscope slide and arranged in an array format [4]. 65 
Cancer stage is known for these TMA specimens and cancer grade is also determined by 66 
pathologists, just like in the case of conventional biopsies. Grading describes the morphology of 67 
the cells, while staging depicts the extent of spreading of cancer. TMAs are also characterized by 68 
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immunohistochemistry [5, 6]. TMAs can be studied by two different MS approaches to acquire 69 
information on molecular composition; either by MALDI imaging or by LC-MS/MS. Proteomics 70 
studies of various cancer TMA cores using MALDI imaging mass spectrometry have already been 71 
reported [7, 8]. These type of analyses generally do not aim to identify specific proteins altered in 72 
cancer but detect m/z signals (molecular features) that change with different cancer phenotypes 73 
and with spatial location. LC-MS/MS analysis is usually another option to study TMA cores [9]. 74 
This can be achieved by scraping off TMA cores and performing shotgun mass spectrometry 75 
analysis. However, these studies are seriously hampered by the limited amount of sample available 76 
(usually 1.5 mm diameter, 5 µm thick cores). To improve sensitivity, several cores are often 77 
scraped off and pooled, but these types of studies are better performed on bulk tissue sections, 78 
rather than TMAs. 79 
MS-based proteomics on prostate cancer tissues has been reviewed extensively [10-13]. 80 
Experimental methodologies include 2DE followed by MALDI-TOF-MS/MS [14]; laser capture 81 
micro-dissection and LC-MS/MS [15]; and SILAC-based quantitative LC-MS/MS [16]. 82 
Considering the small amount of tissue samples obtained for pathological diagnosis it is important 83 
to develop proper sample handling to obtain reliable proteomics data using these specimen. The 84 
aim of this preliminary study was to develop and describe a sufficiently sensitive and reliable LC-85 
MS/MS method for label-free quantitative analysis of individual TMA cores. Digesting very low 86 
amounts of tissue (like scraping off TMA cores) leads to significant sample loss, so we used 87 
surface tissue digestion to improve sensitivity. A previously described tissue surface tissue 88 
digestion protocol [17] was adapted to individual prostate cancer TMA cores. Following surface 89 
digestion, the resulting peptides were extracted from the surface and analyzed by LC-MS/MS. 90 
TMA cores of the same patient as well as patients belonging to the same pathological grade were 91 
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tested. Label-free quantitative proteomics was used to detect proteomic changes occurring among 92 
prostate cancer samples. 93 
 94 
2. Materials and methods 95 
Unless it is stated otherwise, reagents and consumables were purchased from Sigma-Aldrich 96 
(Sigma-Aldrich Kft., Budapest, Hungary). 97 
2.1. Surface digestion of TMA cores 98 
Human formalin fixed paraffin embedded (FFPE) prostate cancer tissue microarray slides (T191a 99 
and T196) were purchased from US Biomax, Inc. (Derwood, MD, USA). Core diameters are 1.5 100 
mm and tissue thickness is 5 µm. Tissue dewaxing and antigen retrieval of the slides was 101 
performed according to a previous protocol [17]. Altogether, the two slides contain 12 different 102 
cases (4 cores/each case) corresponding to Normal (n=2), Grade 1 (n=1), Grade 2 (n=4), Grade 2-103 
3 (n=2) and Grade 3 (n=3) samples. Therefore, in total 48 TMA cores were analyzed (Table 1).  104 
Tryptic digestion on the surface of the TMA cores was based on a previously described protocol 105 
[17]. Briefly, the proteins in the TMA cores were denaturated and alkylated by 1 µL solution 106 
containing 0.1% RapiGest SF (Waters, Milford, MA) + 5 mM DTT + 10% glycerol. The tissue 107 
slide was incubated in a humidified box at 55 ºC for 20 min. Next, 1 µL solution containing 25 108 
mM ammonium bicarbonate + 10 mM iodoacetamide (IAA) + 10% glycerol was added to each 109 
core and incubated in the dark for 20 minutes. 1 µL Trypsin/Lys-C mix (Promega, Madison, WI) 110 
enzyme solution (50 ng/ µL Trypsin/Lys-C mix in 50 mM ammonium bicarbonate and 10% 111 
glycerol) was added in two cycles, followed by three cycles of 1 µL Trypsin (Promega, Madison, 112 
WI) enzyme solution (200 ng/µL Trypsin in 50 mM ammonium bicarbonate and 10% glycerol). 113 
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Each cycle consisted of 40 minutes of incubation at 37 ºC. Total enzymatic digestion time was 200 114 
minutes. Resulting peptides were extracted from the surface of the individual TMA cores manually 115 
by repeated pipetting using 4 x 1.5 µL 10% acetic acid extraction solvent on each core. Samples 116 
were dried in a SpeedVac and desalted using Pierce C18 spin columns (Thermo Fisher Scientific, 117 
Waltham, MA). 118 
2.2. In-solution digestion of TMA cores 119 
To assess the efficiency of surface digestion the obtained proteomics results were compared to 120 
parallel TMA cores that were scraped off the microscope slide and digested in-solution. Tissue 121 
dewaxing and antigen retrieval of the slides was performed as above [17]. After that individual 122 
TMA cores were scraped from the surface of the microscope slide using a needle and transferred 123 
to Eppendorf tubes containing 50 µL lysis buffer (100 mM Tris pH 7.6 + 4% SDS) and incubated 124 
in a block heater at 97 °C for 30 min. The resulting cell lysate was clarified by centrifugation at 125 
16 000 g for 10 minutes. The supernatant was transferred to clean Eppendorf tubes and 9x volume 126 
ice-cold ethanol was added. Proteins were precipitated at -20 ºC overnight. Next day, the pellets 127 
were washed twice with ice-cold ethanol and dissolved in 10 µL of 8 M urea in 50 mM ammonium 128 
bicarbonate. DTT was added at a final concentration of 5 mM and incubated at 37 °C for 30 min. 129 
Alkylation was performed in the dark at room temperature for 30 minutes in the presence of 10 130 
mM IAA. Samples were diluted 10-fold with 50 mM ammonium bicarbonate and 1 µL 10 ng/µL 131 
or 50 ng/µL Trypsin/Lys-C mix (Promega, Madison, WI) was added and incubated at 37 °C for 132 
80 minutes. Next, 1 µL 40 ng/µL or 200 ng/µL Trypsin (Promega, Madison, WI) was added and 133 
the samples were incubated for another 2 hours. Digestion was quenched by the addition of 1 µL 134 
formic acid. Desalting was performed on Pierce C18 spin columns (Thermo Fisher Scientific, 135 
Waltham, MA). 136 
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Note that using “surface” and the conventional “in-solution” digestions discussed above, different 137 
enzyme concentrations were used. We compared the efficiency of the two digestion methods using 138 
the same enzyme concentrations and incubation times. The same samples (replicate Grade 2 139 
biopsies) were digested both in solution following scraping off the tissue from the surface of the 140 
glass slide, and on tissue surface using both low (10 ng/µL Lys-C/Trypsin mix and 40 ng/µL 141 
Trypsin solution) and high enzyme concentrations (50 ng/µL Lys-C/Trypsin mix and 200 ng/µL 142 
Trypsin solution). Each condition was tested on two technical replicates. 143 
 144 
2.3. Mass spectrometry and chromatography analysis 145 
Samples were dissolved in 12 µL solvent (98% water, 2% acetonitrile and 0.1% formic acid) out 146 
of which 6 µL was subjected to nanoLC-MS/MS analysis using a Dionex Ultimate 3000 RSLC 147 
nanoLC (Dionex, Sunnyvale, CA, USA) coupled to a Bruker Maxis II Q-TOF (Bruker Daltonik 148 
GmbH, Bremen, Germany) via CaptiveSpray nanoBooster ionization source. Peptides were 149 
separated on an Acquity M-Class BEH130 C18 analytical column (1.7 µm, 75 µm x 250 mm 150 
Waters, Milford, MA) using gradient elution (4–50% eluent B in 120 minutes) following trapping 151 
on an Acclaim PepMap100 C18 (5 µm, 100 µm x 20 mm, Thermo Fisher Scientific, Waltham, 152 
MA) trap column. Solvent A consisted of water + 0.1% formic acid, while Solvent B was 153 
acetonitrile + 0.1% formic acid. Spectra were collected using a fix cycle time of 2.5 sec and the 154 
following scan speeds: MS spectra were acquired at 3 Hz, while CID was performed on multiply 155 
charged precursors at 16 Hz for abundant ions and at 4 Hz for low abundance ones. Internal 156 
calibration was performed by infusing sodium formate and data were automatically recalibrated 157 
using the Compass Data Analysis software 4.3 (Bruker Daltonik GmbH, Bremen, Germany).  158 
 159 
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2.4. Protein identification and label-free quantitation 160 
Data were processed by the ProteinScape 3.0 software (Bruker Daltonik GmbH, Bremen, 161 
Germany). Proteins were identified by searching against the human Swissprot database (2015_08) 162 
using the Mascot search engine version 2.5 (Matrix Science, London, UK). First, the individual 163 
LC-MS results were searched by Mascot (7 ppm peptide mass tolerance, 0.05 Da fragment mass 164 
tolerance, 2 missed cleavages, carbamidomethylation of cysteines as fixed modification, 165 
deamidation (NQ) and oxidation (M) as variable modifications) and proteins were identified using 166 
1% FDR limit. For additional validation and the comparison of the two types of digestion and the 167 
different cancer grades the resulting Mascot search files were loaded into Scaffold 3.0 software 168 
[18]. The parameters used were the following: 95% probability, minimum 2 peptides identified, 169 
additional X! Tandem identification and all the other parameters were set to default parameters. 170 
Second, the Mascot search results were merged by ProteinScape for all 48 samples; and proteins 171 
were considered identified using strict criteria (ion score criteria was >20 (corresponding to 172 
p<0.01), and FDR < 1%). Label-free quantitation (LFQ) was then performed using MaxQuant [19] 173 
(software version 1.5.3.30), applying its default parameters. MaxQuant analysis searched only for 174 
those proteins, which were identified previously by Mascot (this makes false identification less 175 
likely). Strict acceptance criteria were used, minimum 2 peptides, less than 1% FDR was set both 176 
at the protein and at the peptide level. Each LC-MS/MS run was aligned using the “match between 177 
runs” feature (match time window 0.8 minute, alignment time window 15 minutes). Details of the 178 
parameters of this procedure are given in the Supplementary material (see also Table S-1 and S-179 
2).  180 
 181 
 182 
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2.5. Statistics and bioinformatics 183 
In most studies proteins showing the most significant abundance changes between two groups of 184 
subjects (healthy/cancerous, grade 2-3) are usually selected based either on the degree of fold-185 
change or the statistical significance (p-value of a t-test). A further aspect to consider is protein 186 
abundance: selecting very low abundance proteins based on the fold-change can often be 187 
misleading. We decided to use a combination of these values using the following formula, which 188 
can be considered as a modified p-value:  189 
  =   /(	
 × ∛)        Eq 1. 190 
Where pmod is the modified p-value between healthy and cancerous tissue; the smaller the more 191 
significant; fmod is the modified fold-change, and I is the abundance of the protein (LFQ value). 192 
When the protein abundance is decreased between two samples, the fold-change is a number 193 
between zero and unity. In this case, the modified fold-change will be the reciprocal value of the 194 
fold change (so that fmod is always larger than unity). Due to statistical fluctuations, the fold-change 195 
of low abundance peaks is often unreasonably high. To limit the influence of such fluctuations, 196 
the modified fold-change is limited to maximum 5 (i.e. it will always be between 1 and 5). 197 
Therefore the pmod will be smaller (more significant) under the following conditions: the p-value 198 
is small, the modified fold-change and/or the protein abundance are large. The 200 proteins 199 
showing the most significant changes based on pmod were selected for further study. From this 200 
group, those showing both statistical significance (p < 0.02) and sufficiently high modified fold 201 
change (over 2) between healthy and cancerous samples were selected for protein interaction 202 
analysis (see Table S-3a). Similarly, proteins with p < 0.02 and modified fold change over 1.4 203 
were selected to compare various cancer grades (see Table S-3b).  204 
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Protein interaction analysis was performed using the “Search Tool for Recurring Instances of 205 
Neighboring Genes” (STRING) [20]. Functional enrichment analysis was performed using the 206 
ClueGO plugin [21] of Cytoscape, and the statistical test used for the enrichment was based on the 207 
two-sided hypergeometric option with a kappa score of 0.2. The search was performed against the 208 
GO-Uniprot databases and the KEGG database. XLStat software (Addinsoft, Paris, France) was 209 
used for running non-supervised PCA analysis. 210 
 211 
3. Results and Discussion  212 
3.1. Tissue surface digestion of TMA cores 213 
The method for tissue surface digestion is based on a previously described methodology [17] which 214 
was adapted for TMA analysis. Instead of Trypsin, we used a mixture of Trypsin and Lys-C in the 215 
present protocol, which provides better (more efficient and more complete) digestion. The analysis 216 
was performed using nanoUHPLC-MS/MS using a 2-hour-long linear gradient. Details of the 217 
protocol are described in the Materials and Methods part (2.1.).  218 
The number of proteins identified strongly depends on the type and the size of the sample. In the 219 
present case 386-589 proteins were identified (using Mascot search, validated by Scaffold) from a 220 
single TMA core (1.5 mm diameter, 5 µm thick, ca. 10 µg total mass, 1 µg protein content). The 221 
number of identified proteins on average was 518. This compares favorably with results on mouse 222 
brain and liver tissue sections, where on average 42 proteins were identified using a similar sample 223 
size [17]. 224 
We compared tissue surface analysis with digestion of the bulk tissue by analyzing TMA cores in 225 
duplicates (Fig.1). The same samples (replicate Grade 2 biopsies) were digested both in solution 226 
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following scraping off the tissue from the surface of the glass slide and on tissue surface using both 227 
low and high enzyme concentrations as described at the end of section 2.2, in two technical replicates. 228 
The four groups were compared, shown in a Venn diagram (Fig. 1). The results show that enzyme 229 
concentrations have a relatively small influence. Surface digestion provides between 4.0 and 5.3-fold 230 
increase in the number of identified proteins compared to bulk tissue analysis in solution, depending 231 
on enzyme concentration. Typical contaminant proteins were identified only in scraped-off tissue 232 
samples suggesting that the on-surface digestion is less prone to contamination. 233 
The workflow described in section 2.1. was performed on 4 replicate cores of 12 individuals; 234 
altogether 48 individual TMA cores were studied. The individuals were divided into Normal (i.e. 235 
healthy), Grade 1, Grade 2, Grade 2-3 and Grade 3 groups, based on histological analysis. Results of 236 
Normal, Grade 2 and Grade 3 cancer sample analysis are compared in a Venn diagram (Fig. 2). The 237 
Figure shows that significantly more proteins (by 242) were identified in cancerous than in healthy 238 
tissue.  239 
3.2.Label-free quantitation, analytical reproducibility, and biological variability 240 
The amount of proteins in the various samples has been determined using label-free quantitation. 241 
This was performed by the MaxQuant software [19], using normalized LFQ values. Data are 242 
shown in Table S-1, while identified peptides are listed in Table S-2. 243 
The similarity of two samples based on respective protein abundances, like spectral similarities, 244 
can be compared using correlation coefficients [22]. Here we used Pearson correlation coefficients 245 
to compare protein abundances (MaxQuant LFQ values) among various samples. The correlation 246 
coefficients of protein abundances among technical replicates (pair-wise) vary significantly, from 247 
0.99 to 0.68, the average being 0.93. Replicates showing the worst correlation coefficients 248 
(“outliers”) are due to major, non-statistical variations (e.g. damaged TMA core, mistakes in 249 
12 
 
sample handling, or temporal changes in ESI spray conditions) [23]. In order to improve the 250 
reliability of analysis, these outliers should be left out. To do it in a non-biased way, we discarded 251 
the most outlying experiment out of the 4 technical replicates in each case, based on the correlation 252 
coefficient. The average correlation coefficient among the remaining 3 technical replicates was 253 
0.95 (24% RSD for the 200 most abundant proteins), and there were no major deviations from the 254 
average. These technical replicates were averaged, which reduced the technical error (RSD) of the 255 
average abundance to 13.8%, and we compared this value to the biological variability discussed 256 
below. Note, the standard deviation of the average is equal to the standard deviation of the dataset 257 
divided by the square root of the number of replicates. Technical reproducibility includes errors 258 
not only in sample preparation and analysis but variability among various tissue-slices as well 259 
(different cell assemblies in a given tissue). 260 
The biological variability among all the samples reflects the influence of prostate cancer on cellular 261 
proteomics. This was determined as an average correlation coefficient among the 12 different 262 
samples (0.85), and as the average RSD of the 200 most abundant protein intensities (46.7%), 263 
shown in Table 2. This clearly indicates that the biological variability is much larger than the 264 
technical reproducibility (13.8% RSD). The samples studied may be divided into various groups, 265 
based on cancer stage or cancer grade (Table 1). Among the 12 samples studied, there were 2 266 
healthy, 5 Stage II, 2 Stage III, and 3 Stage IV cases. The average biological variability within the 267 
four groups of patients can be characterized by an average correlation coefficient of 0.92 and an 268 
average RSD of 30.5 % (Table 2). This means that the variability within the various groups is 269 
smaller than among all the samples but it is still larger than the technical reproducibility. The same 270 
samples were grouped together based on cancer grade as well: there were 2 healthy, 1 Grade 1, 4 271 
Grade 2, 3 Grade 3 cases, and 2 of them were assigned as between Grade 2 and 3. The average 272 
biological variability within normal, Grade 2 and Grade 3 cancer types was 0.94 based on the 273 
13 
 
average correlation coefficient, and 28.7% based on average RSD of protein abundances (Table 274 
2). These results show that grouping samples based on grade results in somewhat more uniform 275 
groups than classification based on stage. All of these data are listed in Table 2.  276 
The main purpose of the present communication is to develop a new method and evaluate its 277 
potential in TMA proteomics for exploring molecular changes occurring in prostate cancer. It is a 278 
pilot study since the number of samples analyzed is not large enough to fully describe biological 279 
variations. However, the small number of samples (12) were analyzed in several replicates, so it 280 
is feasible to separate technical errors from biological differences. As discussed above, technical 281 
errors are significantly smaller than the biological variability, corroborating the robustness of the 282 
analytical methodology used. This pilot study is a starting point to map biological differences 283 
among various patient groups and for designing a future, large-scale, statistically relevant study.  284 
3.3. Principal component analysis 285 
Quantitative proteomics (arrays of protein abundances) was used to compare the studied 12 286 
samples using principal component analysis (PCA), and the result is shown in Fig. 3.  287 
The two principal components (linear combination of protein abundances) providing the maximum 288 
variability among the samples are plotted on the two axes in Fig. 3. PCA is an unsupervised 289 
statistical approach, therefore no information on the sample type (i.e. healthy or stage II cancer) is 290 
taken into account; it is important to avoid bias. Fig. 3a shows the results where samples are 291 
distinguished based on cancer stage, while Fig. 3b shows the same data labelled according to 292 
cancer grade. The ovals in Fig. 3 mark the distribution of the various sample types in the plot.  293 
It is shown in Fig. 3 that the healthy samples were clearly separated from all the cancerous 294 
specimens. However, Fig. 3a suggests that protein distribution does not separate the various cancer 295 
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stages from each other. Furthermore, there is no direct progression from Stage II to III and IV but 296 
the individual groups are nearly randomly mixed. This suggests that the overall protein distribution 297 
(i.e. major biochemical processes) cannot distinguish cancer stages reasonably. Fig. 3b shows the 298 
separation of various grade cancer types. Cancerous samples are clearly separated into two groups: 299 
Grade 1, Grade 2 and “uncertain” Grade 2-3 samples belong to one group, while Grade 3 cancer 300 
specimens constitute another group. The results suggest that the protein fingerprint distinguishes 301 
tissue biopsies based on cancer grade. Note, Grade 3 cancer is defined by histology containing 302 
poorly differentiated (i.e. far from healthy) cells. The present results show that the changes in 303 
protein fingerprint relate fairly well to the differences observed in cell structure, while only slight 304 
correlation is depicted with stage which is mainly determined by the spread of cancer or metastasis. 305 
Although the overall protein fingerprint does not correlate with cancer stage, the possibility that 306 
there might be specific minor proteins (or protein pathways) which may reflect metastasis is not 307 
excluded. 308 
Differences among various cancer groups can be studied using correlation coefficients as well. 309 
The average correlation coefficients between protein fingerprints (sets of protein abundances) 310 
within and between various groups based on cancer grade are shown in Table 3. The first column 311 
shows the comparison with healthy subjects: differences in the protein fingerprint between healthy 312 
and cancerous groups increase with higher cancer grade. Table 3 also indicates that samples 313 
obtained from Grade 2-3 and Grade 3 subjects are highly heterogeneous, as evidenced by the small 314 
correlation coefficients both within and between these groups. These findings support conclusions 315 
based on PCA analysis.  316 
3.4. Changes in proteins between healthy and cancerous tissue 317 
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Results can be further evaluated by looking at changes in the abundances of individual proteins. 318 
According to the PCA results, Normal, Grade 2 and Grade 3 subjects form well-separated groups 319 
based on the protein fingerprint. Most proteins can be classified into four groups based on changes 320 
in their abundance: a) housekeeping proteins, b) proteins which show decreasing abundance in the 321 
healthy >>>Grade 2 >>>Grade 3 direction, c) proteins which show increasing abundance in the 322 
healthy <<<Grade 2 <<<Grade 3 direction, and d) proteins which have similar abundance in 323 
healthy and Grade 3 but show increased abundance in Grade 2 cancer. Selected examples for these 324 
four protein groups are shown in Fig. 4, while the relative abundances of all the detected proteins 325 
are shown in the Table S-1. Abundant proteins typically show decreasing abundance in cancer. On 326 
the other hand, over 100 proteins show statistically significant increase with cancer progression.  327 
Proteins showing the most significant abundance changes between healthy and cancerous subjects 328 
were selected based on a t-test, weighted by the fold change and the protein abundance (those with 329 
high fold-change and high abundance were selected preferentially). 15% of all proteins were 330 
selected for further analysis; this limit corresponds to t-test p-value lower than 0.02 and fold-331 
change larger than 2. We used bioinformatics analysis (STRING bioinformatics program) [20] to 332 
identify protein pathways and protein localizations involved in the tumorigenesis of prostate 333 
cancer. The result of STRING analysis is indicated in Fig. 5 using proteins listed in Table S-3a. 334 
Using highly confident protein interactions only, 5 protein groups can be distinguished in Fig. 5, 335 
outlined by the drawn ovals. All proteins present in Group 1 show increased abundance in cancer. 336 
These are ribosomal proteins that participate in biological processes such as translational 337 
elongation and protein localization to organelle (based on gene ontology) and belong to the KEGG 338 
ribosome pathway. This is in agreement with previous studies, showing that various ribosomal 339 
proteins are up-regulated in prostate cancer [24, 25]. Ribosomal protein-based cancer signature 340 
has been recently proposed based on the expression of ribosomal proteins in several human tissues 341 
16 
 
and primary cells [26]. Group 2 proteins also show increased abundance in cancerous samples; 342 
these are involved in mRNA splicing via spliceosome biological process (based on gene ontology). 343 
Group 3 proteins likewise showed over-expression in cancer. These are composed mainly of 344 
histones present in the chromatin assembly. Histone post-translational modifications (e.g. 345 
methylation and acetylation) have been suggested to be involved in prostate tumorigenesis [27, 346 
28]. Group 4 and Group 5 proteins show a decreased abundance in cancerous samples compared 347 
to normal tissue (Fig. 5). Some of these proteins are present in focal adhesion and participate in 348 
actin cytoskeleton organization. Protein Group 5 (highlighted in magenta in Fig. 5) is also a part 349 
of the KEGG pathways in cancer (pathway 05200). Focal adhesions are important in mediating 350 
various signals between the extracellular matrix and interacting cells and are already targeted in 351 
preclinical trials [29]. Cell adhesion molecules are crucial in tumor cell migration. Among these, 352 
we identified basal cell adhesion molecule (BCAM) protein in the current study. This protein has 353 
been shown to promote tumor cell migration by competing with integrins for binding to laminin 354 
subunit alpha-5 [30]. In the present study, the amount of both laminin subunit alpha-5 and integrin 355 
beta-1 decreased significantly in cancerous tissue, while the amount of BCAM increased in 356 
accordance with previous findings.  357 
We performed STRING analysis also on proteins, which show a significant difference in 358 
abundance depending on cancer grade using proteins listed in Table S-3b. To select such proteins, 359 
differences between i) unified group of Grade 1, 2, and 2-3 cancer, and ii) Grade 3 cancer were 360 
considered. Like above, 15% of all proteins were selected based on a weighted t-test. In this case, 361 
the approximate limit was p <0.02 and fold-change >1.4. These represent biological changes 362 
indicative of tumor grade. STRING analysis of these proteins shows two large and one small 363 
cluster (Fig. 6). The amount of all these proteins increased in Grade 3 samples. Proteins in Group 364 
1 are histones and present in the chromatin assembly. Group 2 proteins are mostly ribosomal 365 
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proteins participating in biological processes like translational elongation, mRNA metabolic 366 
process and belong to the KEGG ribosome pathway. Proteins of Group 3 are related to mRNA 367 
metabolic processes. In order to complement the results of the STRING analysis, we performed 368 
additional ClueGO pathway search as well. This way we determined the significance and pathway 369 
coverage of the pathways found using STRING analysis; the numerical values are summarized in 370 
Table S-4a (normal vs cancer) and Table S-4b (between cancer grades). In general, these support 371 
the conclusion of pathway analysis discussed above. 372 
Proteins identified and quantified in the current study were compared to those published in a recent 373 
Review [10] summarizing protein biomarkers of prostate tissue. Using the described sample 374 
preparation method and limited amount of tissue sample, we observed 39 of the 69 proteins 375 
discussed (listed in Table S-5). Most of these proteins were identified by over 10 peptides, so their 376 
identifications are highly reliable. Among these 39 proteins, 10 showed similar quantitative 377 
changes as described in the Review [10], and 9 were among those used in the STRING analysis 378 
described above. The top 20 proteins showing the most significant abundance changes between 379 
healthy and cancerous subjects (based on a t-test, weighted by the fold change and protein 380 
abundance) are listed in Table 4. Among these, 18 were not listed in the Review article. Note that 381 
the results of the protein network study show that most proteins with significantly changing 382 
abundance fit into a few protein pathways. Moreover, these protein pathways (like mRNA splicing 383 
via spliceosome or chromatin assembly) are all implicated in cancer. This is an indirect evidence 384 
that protein identification and selecting those showing the most significant abundance changes are 385 
indeed reasonable, and show high probability that these might be used as prostate cancer 386 
biomarkers. This clearly demonstrates the usefulness of the described method for the identification 387 
of novel further biomarkers.  388 
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 389 
4. Conclusions 390 
The 5-year survival rate in prostate cancer is very high (98.9%), however, it decreases significantly 391 
in the case of metastatic setting (28.5%) [31]. Thus, biomarkers that can predict therapeutic 392 
response or biological aggressiveness could further improve the therapeutic outcome of metastatic 393 
prostate cancer. High-throughput technologies such as proteomics have the potential to find new 394 
biomarkers in order to tailor therapy. A novel surface digestion protocol has been developed for 395 
the proteomic analysis of TMAs. Using the present technique, we were able to detect over 500 396 
proteins from individual prostate TMA cores. This compares favorably with previous results on 397 
surface digestion (42 proteins on average) [17] and also with bulk digestion of scraped-off TMA 398 
cores (between 102 and 136 proteins, shown in this work). Technical reproducibility is about 3 399 
times better than biological variability, calculated based on relative standard deviation, on 400 
correlation coefficients and on principal component analysis. The present pilot study on prostate 401 
cancer suggests that there are major proteomic differences between cancerous and healthy tissue 402 
sections which can be detected by TMA analysis. The pattern of protein abundances characterizes 403 
not only the presence of cancer but correlates with cancer grade as well. A number of proteins 404 
were identified which show significant abundance changes in prostate cancer. These show 405 
significant overlap with prostate cancer tissue biomarkers identified before [10] but include novel 406 
proteins as well. The number of proteins detected was sufficiently large to allow meaningful 407 
bioinformatics analysis. Protein abundance changes tentatively identified several protein pathways 408 
involved in prostate cancer, such as mRNA metabolic processes, mRNA splicing, chromatin 409 
assembly, focal adhesion, and the “pathways in cancer”. Several of these have been previously 410 
implicated in prostate cancer, so it is encouraging that this pilot study consisting of a relatively 411 
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small number of samples was also able to identify these. Moreover, it is promising that in this pilot 412 
study new proteins that discriminate between normal prostate tissue and prostate cancer were 413 
found. Our proteomics method may be used to supplement histological analysis, to identify novel 414 
therapeutic targets and help understand the molecular mechanisms of cancer progression. It is our 415 
hope that this method can be used to investigate prostate cancer using the remnant of prostate 416 
biopsy samples obtained from patients. A full-scale study is therefore warranted and it is in 417 
preparation based on the present results.  418 
 419 
 420 
Supplementary material. (1) Settings of Mascot and MaxQuant software search; (2) Table S-1, 421 
MaxQuant label-free quantitative data; (3) Table S-2, List of peptides used to identify proteins 422 
reported; (4) Table S-3a, Proteins used for STRING analysis when comparing normal vs cancerous 423 
tissue; (5) Table S-3b, Proteins used for STRING analysis when comparing grade1_2_2-3 vs grade 424 
3 tissue; (6) Table S-4a, Pathways verified by ClueGO enrichment analysis when comparing 425 
normal vs cancerous tissue; (7) Table S-4b, Pathways verified by ClueGO enrichment analysis 426 
when comparing grade1_2_2-3 vs grade 3 tissue; (8) Table S-5, List of the 39 proteins found in 427 
the present study, which were implicated in prostate cancer (Tanase et al. 2017, Oncotarget, 8, pp. 428 
18497-18512). 429 
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List of Figures 437 
Figure 1.  Comparison of the number of proteins identified using surface digestion and bulk 438 
digestion of scraped-off TMA cores at low (Fig. 1A) and high (Fig. 1B) enzyme 439 
concentrations. 440 
Each condition was analyzed in duplicates. 441 
Figure 2.  Number of proteins identified using surface digestion of Normal, Grade 2 and 442 
Grade 3 prostate cancer TMA cores in replicates.  443 
Data in the Figure represent a compilation of the results of 36 individual 444 
experiments.  445 
Figure 3. Non-supervised PCA analysis of label-free quantitative proteomics data obtained 446 
on 2 healthy and 10 prostate cancer TMA cores.  447 
Cancerous samples were grouped both according to cancer stage (A) and cancer 448 
grade (B). 449 
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Figure 4. Selected examples of proteins belonging to four proteins groups based on changes 450 
between healthy and cancerous tissue: housekeeping proteins (A), decreasing 451 
proteins (B), increasing proteins (C) and special proteins (D).  452 
Figure 5. STRING analysis of proteins with significantly changing abundance between 453 
healthy and cancerous tissue.  454 
Only protein interactions with high confidence are shown. Protein groups 455 
highlighted in red (1-3) increase in cancer. Protein groups highlighted in blue (4-456 
5) decrease. All proteins in Group 1 and only these belong to the KEGG ribosome 457 
pathway (red nodes). Most proteins in Group 2 belong to GO mRNA splicing via 458 
spliceosome biological process (blue nodes). Most proteins in Group 3 belong to 459 
GO chromatin assembly biological process. Most proteins in Group 4 belong to 460 
GO actin cytoskeleton organization biological process (yellow nodes). Most 461 
proteins in Group 5 (and some outside, the magenta nodes) belong to KEGG 462 
“Pathways in cancer”. 463 
Figure 6. STRING analysis of proteins significantly changing between tumor grades. All 464 
three highlighted protein groups increase in Grade 3 compared to other cancer 465 
grades.  466 
Only protein interactions with high confidence are shown. Most proteins in Group 467 
1 belong to GO chromatin assembly biological process (green nodes); also found 468 
in Fig. 5. Most proteins in Group 2 and Group 3 belong to GO mRNA metabolic 469 
biological process (blue nodes). Most proteins in Group 2 also belong to KEGG 470 
ribosome pathway (red nodes). 471 
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Table 1. Summary of diagnosis, grading and staging information of the samples analysed 569 
Sample Pathology diagnosis Grade  Stage 
N1 Healthy prostate tissue - - 
N2 Healthy prostate tissue - - 
G1 Adenocarcinoma Grade 1 Stage II 
G2A Adenocarcinoma Grade 2 Stage II 
G2B Adenocarcinoma Grade 2 Stage II 
G2C Adenocarcinoma Grade 2 Stage IV 
G2D Adenocarcinoma Grade 2 Stage II 
G23A Adenocarcinoma Grade 2-3 Stage IV 
G23B Adenocarcinoma Grade 2-3 Stage IV 
G3A Adenocarcinoma Grade 3 Stage II 
G3B Adenocarcinoma Grade 3 Stage III 
G3C Adenocarcinoma Grade 3 Stage III 
 570 
  571 
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 572 
Table 2. Technical reproducibility and biological variability of samples based on the label 573 
free quantitative proteomics 574 
 Technical 
reproducibility 
Average 
Technical 
reproducibility 
Individual 
Biological 
variability 
within Stage 
Biological 
variability 
within 
Grade 
Full 
biological 
variability 
Correlation 
coefficient 
0.97* 0.95 0.92 0.94 0.85 
RSD 13.8% 24.0% 30.5% 28.7% 46.7% 
* estimated value 575 
 576 
  577 
29 
 
 578 
Table 3. Average correlation coefficients between protein fingerprints (sets of protein 579 
abundances) within and between various groups, based on cancer grade. 580 
 Normal Grade 1 Grade 2 Grade 2-3 Grade 3 
Normal 0.98 0.90 0.88 0.81 0.68 
Grade 1 0.90 --- 0.94 0.89 0.84 
Grade 2 0.88 0.94 0.95 0.90 0.82 
Grade 2-3 0.81 0.89 0.90 0.78 0.81 
Grade 3 0.68 0.84 0.82 0.81 0.90 
 581 
  582 
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 583 
Table 4. Top 20 proteins showing the most significant abundance changes between healthy 584 
and cancerous subjects (based on a t-test; weighted by the fold change and protein 585 
abundance) 586 
Protein ID Protein name 
Number 
of 
identified 
peptides 
Average 
MaxQuant 
LFQ 
intensity 
Fold 
change 
normal 
vs 
cancerous 
tissue 
T-test 
p value 
normal 
vs 
cancerous 
tissue 
Described 
in Review 
[10] 
SYNEM_HUMAN Synemin 57 7.98E+06 5.8 1.76E-06 No 
HBA_HUMAN 
 
Hemoglobin 
subunit alpha 9 2.40E+07 3.39 2.44E-06 No 
HBB_HUMAN Hemoglobin 
subunit beta 12 2.47E+07 3.28 4.51E-06 No 
MYH11_HUMAN Myosin-11 132 8.76E+07 3.74 2.22E-05 No 
SMTN_HUMAN Smoothelin 17 1.79E+06 3.45 1.05E-05 No 
HBD_HUMAN 
 
Hemoglobin 
subunit delta 9 7.09E+05 5.01 1.5E-05 No 
MYLK_HUMAN 
Myosin light 
chain kinase. 
smooth 
muscle 
21 6.45E+06 2.51 1.86E-05 No 
DESM_HUMAN Desmin 51 6.29E+07 3.39 9.22E-05 Yes 
TPM1_HUMAN Tropomyosin 
alpha-1 chain 24 1.10E+07 2.45 5.02E-05 Yes 
LMAN1_HUMAN Protein ERGIC-53 4 8.95E+05 0.00037 6.3E-05 No 
LMOD1_HUMAN Leiomodin-1 5 9.88E+05 2.27 3.27E-05 No 
LAMA5_HUMAN 
Laminin 
subunit alpha-
5 
30 1.50E+06 3.14 6.44E-05 No 
PA2G4_HUMAN 
Proliferation-
associated 
protein 2G4 
8 4.73E+05 0.00047 7.14E-05 No 
MYL9_HUMAN 
Myosin 
regulatory 
light 
polypeptide 9 
10 8.26E+06 3.85 1.44E-04 No 
FLNC_HUMAN Filamin-C 76 1.33E+07 2.88 4.21E-04 No 
RS6_HUMAN 40S ribosomal protein S6 5 1.23E+06 0.26 3.16E-04 No 
RL11_HUMAN 60S ribosomal protein L11 3 8.34E+05 0.23 4.02E-04 No 
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FUS_HUMAN RNA-binding protein FUS 8 1.06E+06 0.18 5.62E-04 No 
FABPH_HUMAN 
Fatty acid-
binding 
protein. heart 
4 5.58E+05 4.72 4.36E-04 No 
MPCP_HUMAN 
Phosphate 
carrier 
protein. 
mitochondrial 
3 5.91E+05 0.0006 5.02E-04 No 
 587 
 588 
 589 
 590 
 591 
  592 
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